| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-62 |
Sentence |
denotes |
[Potential antiviral therapeutics for 2019 Novel Coronavirus]. |
| TextSentencer_T2 |
63-229 |
Sentence |
denotes |
The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. |
| TextSentencer_T3 |
230-431 |
Sentence |
denotes |
2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). |
| TextSentencer_T4 |
432-646 |
Sentence |
denotes |
Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. |
| TextSentencer_T5 |
647-831 |
Sentence |
denotes |
Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. |
| TextSentencer_T6 |
832-955 |
Sentence |
denotes |
But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials. |
